医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

PADCEV

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: and KEYTRUDA enfortumab vedotin-ejfv EV-302 Trial PADCEV pembrolizumab

2023年09月22日

Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy PADCEV Seagen and Astellas Announce Initial Results

2022年02月15日